76025-62-2

Usage

Uses

Used in Pharmaceutical Industry:
4-Piperidineethanamine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to act as a ligand and a building block in the development of new drugs.
Used in Agrochemical Industry:
Similarly, in the agrochemical sector, 4-Piperidineethanamine serves as an intermediate in the synthesis of agrochemicals, contributing to the creation of effective compounds for agricultural applications.
Used in Organic Chemistry:
4-Piperidineethanamine is utilized as a key component in organic chemistry, where it plays a role in the formation of complex organic molecules and contributes to the advancement of chemical research and development.

Upstream product

• 114998-55-9 4-(2-chloroethyl)-piperidine 

Downstream Products

• 1373042-91-1 C₁₉H₂₆N₆O₃S 
• 1186397-04-5 1-[3β-(4-chlorophenyl)tropane-2β-carbonylamino]-2-[1-[3β-(4-chlorophenyl)tropane-2β-carbonyl]piperidin-4-yl]ethane 
• 190653-88-4 2-[4-(2-amino-ethyl)-piperidin-1-yl]-6-(3-chloro-phenyl-amino)-9-ethyl-9H-purine 

Relevant academic research and scientific papers

4-carbamate-3-methoxy cinnamic acid cyclamine alkyl amide compound, and preparation method and application thereof

The invention discloses a 4-carbamate-3-methoxy cinnamic acid cyclamine alkyl amide compound, and a preparation method and application thereof. The compound prepared in the invention has low toxic and side effect, and can treat neurodegenerative diseases including, but not limited to, vascular dementia, the Alzheimer's disease, the Parkinson's disease, the Huntington's disease, HIV-associated dementia, multiple sclerosis, amyotrophic lateral sclerosis, neuropathic pain, glaucoma and the like.

Amino alcohol derivatives, process for their production and pharmaceutical preparations and reagents containing these compounds

The present invention concerns new amino alcohol derivatives, a process for their production as well as pharmaceutical preparations and reagents which contain these substances. The invention concerns pharmaceutical agents of the general formula I in which A denotes hydrogen, a group NR1R2, a group NR1(CH2)pNR3R4, a group (C═NH)NH2 or a pyridinyl residue, B and D are the same or different and each denotes a bond, a C1 to C6 alkylene residue or a group NR5—C2 to C6-alkylene, C denotes piperidinediyl or piperazinediyl, W and X are the same or different and each denotes a bond or a carbonyl group, Y and Z are the same or different and each denotes a saturated or unsaturated hydrocarbon residue with 7 to 24 carbon atoms, R1 to R5are the same or different and each represents hydrogen or a C1 to C6 alkyl residue, m is an integer 0, 1 or 2 and if m equals 2 C can also independently of one another be piperidinediyl or piperazinediyl, n and o are the same or different and each denotes the integers 2, 3 or 4 and p denotes an integer from 2 to 6 as well as physiologically tolerated salts thereof, provided that hydrazine derivatives are not included and that m cannot be 0 if A denotes hydrogen or a group (C═NH)NH2 and B and D being the same or different represent a bond or an alkylene residue.